$0.51
arrow_drop_down11.31%Performance History
| Key Stats | |
|---|---|
| Open | $0.54 |
| Prev. Close | $0.58 |
| EPS | -0.93 |
| Dividend | Non-Dividend |
| Next Earnings Date | - |
| Dividend Yield % | - |
| Market Cap | $23.26M |
| PE Ratio | - |
| LOW | HIGH | |
|---|---|---|
| Day Range | 0.51 | 0.54 |
| 52 Week Range | 0.51 | 2.95 |
| Ratios | |
|---|---|
| Revenue | - |
| EBITDA Margin % | - |
| EPS | -0.93 |
Score Breakdown
Welcome to Stocklytics
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Analyst Forecast
Period: Next 12 Months
•Analyst Ratings
About Cognition Therapeutics (CGTX)
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ms. Lisa Ricciardi
- Headquarters
- Purchase
- Employees
- 22
- Exchange
- NASDAQ
Keep an eye on Cognition Therapeutics
Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Frequently Asked Questions
What is Cognition Therapeutics's (CGTX) price per share?
What is the 52-week high and low for Cognition Therapeutics (CGTX)?
Is Cognition Therapeutics (CGTX) a growth stock?
What is Cognition Therapeutics (CGTX) stock price performance year to date (YTD)?
Is Cognition Therapeutics (CGTX) a profitable company?
What is the market capitalization of Cognition Therapeutics (CGTX)?
News
Catalyst Accelerator Ogden Selects 11 Companies for Fall 2024 Cohort in Partnership with the Department of the Air Force Digital Transformation Office
Results from Cognition Therapeutics’ Phase 2 SHINE Study of CT1812 in Mild-to-Moderate Alzheimer’s Disease Accepted for Presentation at AAIC
Cognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's Disease
Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business Update
Cognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy Bodies
Cognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s Disease